MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis

Ivan O. Rosas1*, Thomas J. Richards1*, Kazuhisa Konishi1, Yingze Zhang1, Kevin Gibson1, Anna E. Lokshin2,3, Kathleen O. Lindell1, Jose Cisneros4, Sandra D. MacDonald5, Annie Pardo6, Frank Sciurba1, James Dauber1, Moises Selman4*, Bernadette R. Gochuico5*, Naftali Kaminski1*

1 Dorothy P. and Richard P. Simmons Center for Interstitial Lung Diseases, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America, 2 Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America, 3 University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America, 4 Instituto Nacional de Enfermedades Respiratorias, México DF, México, 5 Pulmonary-Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States of America, 6 Facultad de Ciencias, Universidad Nacional Autónoma de México, México, México

Funding: NK, KG, TJR, YZ, JD, KOL, and MS were supported by National Institute of Health (NIH) grants HL073745, HL0793941, HL0894932, and a generous donation from the Simmons family. IOR, SDM, and BRG were supported by the Division of Intramural Research of the National Heart, Lung, and Blood Institute (NHBLI). MS and AP were supported by Universidad Nacional Autónoma de México Grant SDIPTD05.6. The funding institutions have not been involved in study design, data collection, interpretation, or preparation of this manuscript.

Competing Interests: NK is a recipient of investigator initiated research grants from Biogen Idec and from Centocor for genomic and proteomic biomarker discovery and validation. Data presented in this paper were not funded by any of these grants. FS, as a consultant, has received less than $10,000 from GlaxoSmithKline (GSK) and AstraZeneca. All other authors declared no competing interests.

Academic Editor: Peter Barnes, National Heart and Lung Institute, United Kingdom


Background

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic lung disease associated with substantial morbidity and mortality. The objective of this study was to determine whether there is a peripheral blood protein signature in IPF and whether components of this signature may serve as biomarkers for disease presence and progression.

Methods and Findings

We analyzed the concentrations of 49 proteins in the plasma of 74 patients with IPF and in the plasma of 53 control individuals. We identified a combinatorial signature of five proteins—MMP7, MMP1, MMP8, IGFBP1, and TNFRSF1A—that was sufficient to distinguish patients from controls with a sensitivity of 98.6% (95% confidence interval [CI] 92.7%–100%) and specificity of 98.1% (95% CI 89.9%–100%). Increases in MMP1 and MMP7 were also observed in lung tissue and bronchoalveolar lavage fluid obtained from IPF patients. MMP7 and MMP1 plasma concentrations were not increased in patients with chronic obstructive pulmonary disease or sarcoidosis and distinguished IPF compared to subacute/chronic hypersensitivity pneumonitis, a disease that may mimic IPF, with a sensitivity of 96.3% (95% CI 81.0%–100%) and specificity of 87.2% (95% CI 72.6%–95.7%). We verified our results in an independent validation cohort composed of patients with IPF, familial pulmonary fibrosis, subclinical interstitial lung disease (ILD), as well as with control individuals. MMP7 and MMP1 concentrations were significantly higher in IPF patients compared to controls in this cohort. Furthermore, MMP7 concentrations were elevated in patients with subclinical ILD and negatively correlated with percent predicted forced vital capacity (FVC%) and percent predicted carbon monoxide diffusing capacity (DLCO%).

Conclusions

Our experiments provide the first evidence for a peripheral blood protein signature in IPF to our knowledge. The two main components of this signature, MMP7 and MMP1, are overexpressed in the lung microenvironment and distinguish IPF from other chronic lung diseases. Additionally, increased MMP7 concentration may be indicative of asymptomatic ILD and reflect disease progression.

The Editors’ Summary of this article follows the references.
Introduction

Idiopathic pulmonary fibrosis (IPF), a progressive fibrotic interstitial lung disease (ILD) with median survival of 2.5–3 y, is largely unaffected by currently available medical therapies [1]. The disease is characterized by alveolar epithelial cell injury and activation, fibroblast/myofibroblast foci formation, and exaggerated accumulation of extracellular matrix in the lung parenchyma. Recent studies employing high-throughput genomic technologies to analyze samples from IPF patients or genetically modified animals have highlighted the complexity of the pathways involved in the disease (reviewed in [2–4]). While these studies have improved the understanding of the molecular mechanisms underlying lung fibrosis, they did not translate well into the clinical arena.

Identification of peripheral blood biomarkers may facilitate the diagnosis and follow-up of patients with IPF as well as the implementation of new therapeutic interventions. Currently, establishing a diagnosis of IPF may require surgical lung biopsy in patients with atypical clinical presentations or high-resolution computed tomography (HRCT) scans. Patients with IPF are often evaluated by serial pulmonary physiology measurements and repeated radiographic examinations. These studies provide a general assessment of the extent of disease, but do not provide information about disease activity on a molecular level. Higher serum concentrations of surfactant proteins [5], KL-6 [6], FASL [7], CCL-2 [8], α-defensins [9], and most recently SPP1 [10] have been reported in patients with IPF and other ILDs, but most of these studies were modest in size and assayed only a single or a few protein markers simultaneously.

In this study, we used a multianalyte protein assay system to simultaneously measure concentrations of 49 plasma proteins, including cytokines, chemokines, growth and angiogenic factors, matrix metalloproteases (MMPs), and markers of apoptosis in a derivation cohort comprised of IPF patients and healthy controls. We identified a combinatorial signature of five proteins; of these, we measured concentrations of two metalloproteases, MMP7 and MMP1, in other chronic lung diseases and compared them to the levels observed in IPF patients. Finally, the potential role of MMP7 and MMP1 as IPF peripheral blood biomarkers was tested in an independent validation cohort.

Table 1. Derivation Cohort Patient Characteristics

<table>
<thead>
<tr>
<th>Variables</th>
<th>Characteristics</th>
<th>IPF (n = 74)</th>
<th>Control (n = 53)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>Male</td>
<td>49 (66.2%)</td>
<td>22 (41.5%)</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>25 (33.8%)</td>
<td>31 (58.5%)</td>
</tr>
<tr>
<td>Race</td>
<td>European descent</td>
<td>73 (98.6%)</td>
<td>47 (88.7%)</td>
</tr>
<tr>
<td></td>
<td>African American</td>
<td>1 (1.4%)</td>
<td>4 (7.5%)</td>
</tr>
<tr>
<td></td>
<td>Unknown</td>
<td>0 (0.0%)</td>
<td>2 (3.8%)</td>
</tr>
<tr>
<td>Smoking</td>
<td>Current</td>
<td>2 (2.7%)</td>
<td>3 (5.7%)</td>
</tr>
<tr>
<td></td>
<td>Former</td>
<td>56 (75.7%)</td>
<td>22 (41.5%)</td>
</tr>
<tr>
<td></td>
<td>Never</td>
<td>16 (21.6%)</td>
<td>26 (49.1%)</td>
</tr>
<tr>
<td></td>
<td>Unknown</td>
<td>0 (0.0%)</td>
<td>2 (3.8%)</td>
</tr>
<tr>
<td>Age (y)</td>
<td>Mean ± SD</td>
<td>65.9 ± 9.4</td>
<td>50.5 ± 15.7</td>
</tr>
</tbody>
</table>

Methods

For detailed description of the methods used in this study, see Text S1.

Initial IPF Derivation Cohort

This study included 74 patients with IPF evaluated at the University of Pittsburgh Medical Center. The diagnosis of IPF was established on the basis of published criteria [11], and surgical lung biopsy when clinically indicated [12] (see Text S1). Clinical data were available through the Simmons Center database. Smoking status was defined as previously described [13]. Fifty-three control individuals were obtained from the pulmonary division sample collection core. Baseline demographic information is detailed in Table 1. The mean percent predicted forced vital capacity (FVC%) of IPF patients was $61.9 \pm 20.8$; mean percent predicted carbon monoxide diffusing capacity (DLCO%) was $42.1 \pm 17.4$.

Chronic Obstructive Pulmonary Disease

Plasma samples from 73 patients with chronic obstructive pulmonary disease (COPD) evaluated at the University of Pittsburgh were available for this study. Individuals were clinically stable at the time of examination, had tobacco exposure of at least ten pack years, and had no clinical diagnosis of rheumatologic, infectious, or other systemic inflammatory disease. Disease severity was measured using the GOLD classification as previously described [14]. The COPD cohort included 13 patients with GOLD class 0–I, 21 patients with GOLD II, and 39 patients with GOLD III–IV.

Sarcoidosis

Plasma samples from 47 patients with sarcoidosis evaluated at the University of Pittsburgh Medical Center were tested. Patients with lung disease ($n = 29$) demonstrated an average FVC% of $76.7 \pm 22.1$, and average DLCO% of $72.9 \pm 25.5$. The diagnosis and staging of disease was determined according to American Thoracic Society and European Respiratory Society criteria, as previously described [15,16].

Hypersensitivity Pneumonitis

Serum samples from 41 patients with subacute/chronic hypersensitivity pneumonitis (HP) and 34 patients with IPF evaluated at Instituto Nacional de Enfermedades Respiratorias in Mexico were available for this study. Diagnosis of IPF
and HP has been previously described for this cohort [17,18]. Briefly, HP patients showed the following features: (a) antecedent bird exposure and positive serum antibodies against avian antigens; (b) clinical and functional features of ILD; (c) HRCT showing diffuse centrilobular poorly defined micronodules, ground glass attenuation, focal air trapping, and mild to moderate fibrotic changes; and (d) greater than 35% lymphocytes in bronchoalveolar lavage (BAL) fluid. Forty-four percent of the patients had a surgical lung biopsy; in all cases lung histology was consistent with the diagnosis of HP. The average FVC% was 60.3 ± 15.3 for HP and 59.1 ± 17.2 for IPF patients.

Independent Validation Cohort

Serum samples from 20 control individuals, eight patients with subclinical idiopathic ILD, 16 patients with familial pulmonary fibrosis, and nine with sporadic IPF, evaluated at the Warren Grant Magnuson Clinical Center of the National Institutes of Health (NIH), were available for this study. Patients with subclinical disease were first-degree relatives of patients with familial pulmonary fibrosis; they were asymptomatic, with normal pulmonary function tests but HRCT findings consistent with early ILD. Familial pulmonary fibrosis was defined as previously described [19]. Normal volunteers were used as controls.

These cohorts have been previously described by us [20,21]. Briefly, the mean FVC% values for patients with sporadic IPF and familial pulmonary fibrosis were 59.4 ± 19.7 and 75.7 ± 16.7, respectively. Eight patients with familial pulmonary fibrosis were diagnosed with early asymptomatic ILD using HRCT [21]; the mean FVC% in this group was 101.3 ± 10.1. Gender, age, ethnic origin, and smoking status for all groups are presented in Table 2.

Lung tissue samples for microarray analysis were obtained through the University of Pittsburgh Health Sciences Tissue Bank as we previously described [22]. Twenty-three samples were obtained from surgical remnants of biopsies or lungs explanted from patients with IPF who underwent pulmonary transplant and 14 control normal lung tissues obtained from the disease free margins with normal histology of lung cancer resection specimens. The morphologic diagnosis of IPF was based on typical microscopic findings consistent with usual interstitial pneumonia [12,23]. All patients fulfilled the diagnostic criteria for IPF outlined by the American Thoracic Society and European Respiratory Society [11]. All studies were approved by the Institutional Review Board at the University of Pittsburgh, the National Heart, Lung, and Blood Institute, or the National Institute of Respiratory Diseases, Mexico. Informed consent was obtained from all patients.

Blood Samples

Blood (45 ml) was drawn from participants using standardized phlebotomy procedures. Plasma or serum was separated by centrifugation, and all specimens were immediately aliquoted and frozen.

BAL

BAL was performed through flexible fiberoptic bronchoscopy as part of the diagnostic process, as we previously described [18,22,24]. Supernatants were kept at −70 °C until use. BAL samples from 22 IPF patients (age 62.2 ± 7.2 y) and ten normal controls (age 41.5 ± 5 y) were available for this study.

Multiplex Analysis

Assays were performed using Luminex xMAP technology (Luminex Corporation) in 96-well microplate format according to appropriate manufacturers’ protocols (Invitrogen and R&D Systems), as previously described [25] and in Text S1.

Bead-Based Immunoassays

A 34-plex assay was performed for IL1A, IL1RA, IL1B, IL2, IL2R, IL4, IL5, IL6, IL7, IL8, IL10, IL12B, IL13, IL15, IL17, TNFA, IFNA, IFNG, GMCSF, EGF, VEGF, GCSEF, FGF2, HGF, CXCL9, CXCL10, CCL2, CCL3, CCL4, CCL5, CCL11, TNFR51A, TNFR51B, and TRAIL-R2 (Invitrogen). MMP assays included MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP12, and MMP13 (R&D Systems).

Assays for FAS, EGF, FASL, Cyfra 21–1 (CKRT19 fragment), IGFBP1, and KLK10 were developed in our Pittsburgh Luminex Core Facility. The assays were validated as described [25].

ELISA

Quantitative sandwich enzyme immunoassay for human MMP1, MMP7, and AGER was performed as recommended by the manufacturer (R&D Systems).

Oligonucleotide Microarray Experiments

Detailed information is provided in Text S1. Briefly, total RNA was used as a template for synthesis of cDNA as

Table 2. Validation Cohort Patient Characteristics

<table>
<thead>
<tr>
<th>Variables</th>
<th>Characteristics</th>
<th>Sporadic IPF (n = 9)</th>
<th>Control (n = 20)</th>
<th>Subclinical ILD (n = 8)</th>
<th>Familial IPF (n = 16)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td>2 (22%)</td>
<td>9 (45%)</td>
<td>6 (75%)</td>
<td>7 (44%)</td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td>7 (78%)</td>
<td>11 (55%)</td>
<td>2 (25%)</td>
<td>9 (56%)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>European descent</td>
<td></td>
<td>7 (78%)</td>
<td>15 (75%)</td>
<td>7 (87%)</td>
<td>15 (94%)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>0 (0%)</td>
<td>1 (5%)</td>
<td>1 (13%)</td>
<td>1 (6%)</td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>2 (22%)</td>
<td>1 (5%)</td>
<td>0 (0%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>African American</td>
<td>0 (0%)</td>
<td>3 (15%)</td>
<td>0 (0%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>2 (24%)</td>
<td>2 (18%)</td>
<td></td>
</tr>
<tr>
<td>Former</td>
<td>3 (33%)</td>
<td>6 (30%)</td>
<td>1 (13%)</td>
<td>6 (35%)</td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>6 (67%)</td>
<td>14 (70%)</td>
<td>5 (63%)</td>
<td>8 (47%)</td>
<td></td>
</tr>
<tr>
<td>Age (y)</td>
<td>Mean ± SD</td>
<td>66 ± 8</td>
<td>39 ± 17</td>
<td>49 ± 11</td>
<td>64 ± 11</td>
</tr>
</tbody>
</table>

doi:10.1371/journal.pmed.0050093.t002

**Table 2**. Validation Cohort Patient Characteristics
Peripheral Blood Proteins in IPF

To determine whether concentrations of MMP7 and MMP1 are increased in patients with chronic lung diseases, we measured plasma concentrations in patients with sarcoidosis or COPD. The 47 sarcoidosis patients were stratified into those with evidence for parenchymal lung disease (stage 2 or greater; \( n = 29 \)) and those with no lung parenchymal involvement (\( n = 18 \)). As shown in Figure 3, there are no significant differences in plasma concentrations of MMP7 (\( p = 0.78 \)) or MMP1 (\( p = 0.27 \)) between the sarcoidosis groups with or without lung abnormalities when compared to controls. COPD participants were grouped by GOLD class, into \( 0-1 \) (\( n = 13 \)), \( II \) (\( n = 21 \)), and \( III-IV \) (\( n = 39 \)). No significant differences are found in plasma concentrations of MMP7 (\( p = 0.21 \)) or MMP1 (\( p = 0.85 \)) between groups of COPD patients stratified by GOLD class (Figure 3A and 3B, respectively).
MMP7 and MMP1 Are Significantly Higher in the Serum of Patients with IPF Compared to Patients with HP

To determine whether peripheral blood concentrations of MMP7 and MMP1 distinguish IPF from other common forms of ILD, we measured their levels in 41 patients with HP and 34 patients with IPF. Univariately, serum concentrations of MMP7 (p = 0.01) and MMP1 (p < 0.001) are significantly higher in IPF compared to HP; fold changes for MMP1 and MMP7 are 2.3 and 1.31, respectively (Figure 4A and 4B).

Similar results are observed in a reanalysis of a previously published DNA microarray dataset comparing gene expression in lung tissue obtained from IPF and HP patients [18]. In this reanalysis, MMP7 and MMP1 levels are significantly higher in IPF compared to HP (false discovery rate [FDR] < 5%), however, as observed in the peripheral blood, the change in MMP7 levels is moderate when compared to the increase in MMP1 (Figure 4C).

Combinations of serum MMP1 and MMP7 concentrations have positive predictive values for determining that a patient has IPF ranging from 91% (MMP7 > 2.6 ng/ml and MMP1 > 8.9 ng/ml) to 66%, and negative predictive value (ruling out IPF) ranging from 96% (MMP7 < 2.9 ng/ml and MMP1 >
3.5 ng/ml) to 70% (Figure 4D). Additionally, the combination of high MMP7 and high MMP1 peripheral blood concentrations distinguish IPF from HP with 96.3% sensitivity (95% CI 81.0%–100%) and 87.2% specificity (95% CI 72.6%–95.7%) (Figure 4E), further supporting that MMP1 in combination with MMP7 distinguishes IPF from HP.

**MMP7 and MMP1 Are Significantly Higher in the Serum of an Independent Validation Cohort**

To verify our findings, we measured serum concentrations of MMP7 and MMP1 in an independent validation cohort comprised of patients affected with IPF, familial pulmonary fibrosis, or subclinical ILD, and control individuals. This cohort has been recently described by us [21]. Even though concentrations were measured in serum and not plasma, significantly higher concentrations of MMP7 and MMP1 are found in patients with pulmonary fibrosis compared to controls ($p < 0.001$ and $p = 0.01$, respectively). Notably, serum MMP7 concentrations in patients with subclinical ILD are significantly higher compared to control individuals ($p = 0.019$) and significantly lower compared to patients with full-blown IPF ($p < 0.0001$) (Figure 5A), suggesting that MMP7 may serve as a biomarker for disease progression. There is no significant difference in MMP7 concentrations between patients with familial or sporadic IPF, consistent with the findings of Yang et al. [30].

In this cohort, elevated MMP1 concentrations combined with high concentrations of MMP7 can distinguish IPF from controls with 89.2% sensitivity (95% CI 71.8%–91.7%) and 95.0% specificity (95% CI 75.1%–99.9%), supporting the findings in our derivation cohort (Figure 5B).

**MMP7 Concentrations Correlate Moderately with Disease Severity**

To determine whether concentrations of MMP7 or MMP1 correlate with disease severity, we compared pulmonary function measurements with serum concentrations of MMP7 and MMP1 in the validation cohort. We found a significant correlation between higher MMP7 concentrations and disease severity as measured by FVC% (Figure 5C) and DLCO% (Figure 5D). Fitted models predict a decline of 4.1% in DLCO% ($p = 0.002$, $r = -0.55$) and 4.0% in FVC% ($p = 0.002$, $r = -0.51$) for each increment of 1 ng/ml in serum MMP7. We did not find any statistically significant correlation between

### Table 3. Plasma Proteins That Distinguish IPF from Controls

<table>
<thead>
<tr>
<th>Protein</th>
<th>Fold</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>MMP1</td>
<td>4.6</td>
<td>&lt;0.000001</td>
</tr>
<tr>
<td>MMP7</td>
<td>3.2</td>
<td>&lt;0.000001</td>
</tr>
<tr>
<td>MMP8</td>
<td>2.6</td>
<td>&lt;0.000001</td>
</tr>
<tr>
<td>CXCL10</td>
<td>2.3</td>
<td>&lt;0.000001</td>
</tr>
<tr>
<td>MMP9</td>
<td>2</td>
<td>&lt;0.000001</td>
</tr>
<tr>
<td>TNFRSF1A</td>
<td>1.8</td>
<td>&lt;0.000001</td>
</tr>
<tr>
<td>MMP3</td>
<td>1.8</td>
<td>&lt;0.000001</td>
</tr>
<tr>
<td>AGER</td>
<td>0.66</td>
<td>&lt;0.000001</td>
</tr>
<tr>
<td>FAS</td>
<td>1.7</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>CCL11</td>
<td>1.7</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>TNFRSF1B</td>
<td>1.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL12B</td>
<td>1.3</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

doi:10.1371/journal.pmed.0050093.t003

![Figure 2](image-url)
MMP1 concentrations and pulmonary function measurements (unpublished data).

**Discussion**

Overall, our study demonstrates the first evidence for a peripheral blood protein signature in IPF patients to our knowledge. MMP7 and MMP1, two matrix metalloproteases previously implicated in the pathogenesis of IPF [31], are significantly increased in plasma, serum, BAL fluid, and lung tissue of IPF patients, suggesting that increased MMP7 and MMP1 levels in the peripheral blood are indicative of the pathologic changes that characterize the IPF alveolar microenvironment. Used in combination, blood levels of MMP1 and MMP7 can distinguish IPF patients from diverse types of chronic lung disease including HP, a common interstitial pneumonia that can sometimes be indistinguishable from IPF [32–34]. Increases in MMP7 blood concentrations are observed in patients with subclinical familial pulmonary fibrosis, and higher levels of MMP7 are associated with disease severity. Taken together our findings support the use of MMP1 and MMP7 as IPF biomarkers and suggest that their role in diagnosis, early detection, and monitoring of disease progression should be further investigated.

Multiple MMPs are among the 12 proteins significantly increased in the blood of IPF patients. The roles of MMPs have been intensively studied and debated in IPF [35]. While multiple and often contrasting roles have been proposed for MMPs in regulating abnormal epithelial response to injury, fibroblast proliferation, extracellular matrix accumulation, and aberrant tissue remodeling, the consensus is that this family of matrix degrading enzymes is involved in disease pathogenesis [31,36–40]. The two top-ranked proteins in this study are MMPs known to be significantly overexpressed in the activated alveolar epithelium in IPF lungs. MMP1, a matrix metalloprotease that primarily degrades fibrillar collagen, is rare expressed under normal conditions, but is highly overexpressed in reactive alveolar epithelial cells in IPF lungs [39]. MMP7, a matrix metalloprotease with multiple local inflammatory regulatory roles [41,42], is also highly upregulated in alveolar epithelial cells in IPF [39,43]. Furthermore, MMP7 knockout mice are relatively protected from bleomycin-induced fibrosis [39], suggesting that MMP7 may have a profibrotic effect in IPF. Taken in the above context, our results strongly suggest that activated epithelial cells in IPF lungs are the likely source of elevated peripheral blood concentrations of MMP1 and MMP7, thus supporting their use as biomarkers for disease detection and progression.

Our data show that neither patients with COPD, a chronic progressive lung disease, nor patients with sarcoidosis, a chronic granulomatous ILD, express significantly increased peripheral blood concentrations of MMP7 or MMP1. Further, elevated peripheral blood MMP1 concentrations, in the presence of elevated MMP7 concentrations, distinguish IPF from HP. A similar trend in gene expression of MMP7 and MMP1 is found in the lungs of patients with IPF and HP, further supporting the notion that the changes in peripheral blood concentrations of MMP7 and MMP1 are reflective of the lung gene environment and constitute a disease-specific signal. This finding may be very important clinically, because subacute HP is frequently misdiagnosed as idiopathic non-specific interstitial pneumonia (NSIP), and in its chronic advanced form HP can be undistinguishable from IPF [32–34]. In fact, recent studies have demonstrated that histopathologic and HRCT abnormalities observed in chronic HP often overlap with those of usual interstitial pneumonia (UIP), representing an important challenge to the differential diagnosis of these conditions [33,34,44]. Thus, the elevated peripheral blood concentrations of MMP7 and MMP1 observed in IPF are not due to a systemic stress response to a chronic lung disease and distinguish COPD, sarcoidosis, and HP from IPF. While we do not advocate at this stage relying solely on peripheral blood concentrations of MMP7 and MMP1 in distinguishing IPF from HP, sarcoidosis, or the less difficult differential diagnosis of COPD, it seems likely that knowing these concentrations will impact clinical decision making.

We did not compare IPF to other idiopathic interstitial pneumonias such as NSIP. There is nothing in our data to suggest that we can distinguish IPF from these diseases using MMP7 and MMP1 peripheral blood concentrations. In fact...
the finding of elevated MMP7 in patients with subclinical ILD may be indicative that this increase may be present in other idiopathic ILDs. Furthermore, gene expression patterns were found to be extremely similar in IPF and NSIP [30,45], and BAL MMP7 levels were also recently found to be similar in patients with IPF and NSIP [46]. The major limitation in these studies was the small number of cases with NSIP because of the substantial rarity of isolated NSIP. Therefore our results should encourage the establishment of multicenter collections of peripheral blood samples of patients with ILD with sufficient power to determine whether NSIP and IPF differ in their peripheral blood protein expression.

In comparison to other studies, major attributes of our analysis include the relatively large size of our derivation cohort and the large number of proteins assayed in this cohort of patients with IPF, the comparison of peripheral blood biomarker levels with their gene expression levels in the lungs and BAL, the comparison with multiple relatively large control populations with other chronic lung diseases to establish specificity of our findings, and the verification of our initial results in an independent validation cohort. A unique feature of our validation cohort is that it contains patients with subclinical ILD who are asymptomatic first-degree relatives of patients affected with familial IPF. These individuals have HRCT findings of early ILD, but do not have pulmonary function abnormalities, cough, or dyspnea [19,21]. Analysis of samples from this cohort allowed us to demonstrate that MMP7 concentrations are significantly higher in patients with early subclinical lung disease, suggesting that MMP7 may be a marker for early asymptomatic ILD. Peripheral blood concentrations of MMP7 also correlate with pulmonary function tests, which are surrogate measures of disease severity and thus may reflect molecular mechanisms of lung remodeling in IPF [31]. Naturally, the use of different platforms and different sample types limits our ability at this stage to set a disease-specific MMP concentration threshold.

![Figure 4. MMP7 and MMP1 Serum Concentrations Are Higher in IPF, Compared to HP](https://www.plosmedicine.org/doi/10.1371/journal.pmed.0050093.g004)
However, the reproducibility and concordance of our results across different sample types and in multiple cohorts suggest that such a threshold can and should be determined.

In conclusion, in this study we report for the first time to our knowledge the presence of a peripheral blood protein signature in a disease that is confined to the lung. This signature is composed of MMPs, TNF receptors, and some chemokines. Our data demonstrate that peripheral blood increases in two of these markers (MMP1 and MMP7) are also observed in lung and may be specific to IPF. We provide verification of our observations in an independent validation cohort and show that MMP7 concentration (ng/ml) to FVC% and DLCO%. *p < 0.05, **p < 0.01, and ***p < 0.001.

doi:10.1371/journal.pmed.0050093.g005

Figure 5. MMP7 Concentrations Significantly Distinguish Control from Subclinical ILD, Familial, or Sporadic IPF
(A) Dark solid lines show median concentrations in each group. The interquartile range (IR) or middle 50% of concentrations is delimited by a box. Data are expressed on a log base 2 scale.
(B) ROC curves for using MMP1 or MMP7, or their combination, to classify samples as IPF (sporadic or familial) or control in validation cohort.
(C and D) Serum MMP7 concentrations moderately correlate with decreases in FVC% (C) and DLCO% (D). Linear regressions and 95% CI inversely relate MMP7 concentration (ng/ml) to FVC% and DLCO%. *p < 0.05, **p < 0.01, and ***p < 0.001.

Supporting Information

Alternative Language Abstract S1. Russian Translation of the Abstract by Anna E. Lokshin
Found at doi:10.1371/journal.pmed.0050093.sd001 (24 KB DOC).

Alternative Language Abstract S2. Spanish Translation of the Abstract by Moises Selman
Found at doi:10.1371/journal.pmed.0050093.sd002 (42 KB DOC).

Accession Numbers
The Entrez Gene IDs (http://www.ncbi.nlm.nih.gov/sites/entrez) of the proteins discussed in this paper are: AGER, 177; CCL11, 6356; CXCL10, 3627; IL12B, 3593; IGFBP1, 3484; MMP1, 4312; MMP3, 4314; MMP7, 4316; MMP8, 4317; MMP9, 5318; TNFRSF1A, 7132; TNFRSF1B, 7133.

Acknowledgments
The authors wish to thank L. Chensny, A. Marrangoni, K. Johnson, and M. Bisceglia for their help in processing the samples and D. Plaskon for maintaining the database. A. Choi, J. Moss, E. Feingold, and J. Lee provided useful discussions and suggestions. This research would not have been possible without the cooperation of the patients of the Simmons Center and the Pulmonary-Critical Care Medicine Branch.

Author contributions. IOR contributed to recruitment and analysis of the validation cohort, data analysis, conceptualization and design of the study, data analysis, and manuscript preparation. TJR
Peripheral Blood Proteins in IPF

...contributed to project conceptualization, data analysis, statistics, and writing of the initial draft of the paper. KK contributed to microarray data generation and analysis, conceptualization of the study, and manuscript generation. YZ contributed to sample collection and protocol development, data analysis, and manuscript generation. KG contributed to participant recruitment, diagnosis, and ascertainment of the sarcoidosis cohort as well as the validation cohort, protocol development, planning of experiments, and manuscript preparation. AEL contributed to Luminex data generation including custom assays and data analysis. KOL contributed to participant recruitment and diagnosis ascertainment of the derivation cohort, protocol development, and manuscript preparation. JR contributed to participant recruitment and diagnosis ascertainment of the HP cohort, ELISA assays, data analysis, and manuscript preparation. SM contributed to participant recruitment and diagnosis ascertainment of the validation cohort, protocol development, and manuscript preparation. NR contributed to data analysis and manuscript preparation. FS contributed to participant recruitment and diagnosis ascertainment of the COPD cohort, protocol development, and manuscript preparation. JD contributed to conceptualization of proposed studies, diagnosis ascertainment of the derivation cohort, data analysis, and manuscript preparation. MS contributed to participant recruitment and diagnosis ascertainment of all Mexican patient cohorts, planning of the study, preparation of early drafts, and manuscript development. BRG contributed to design and conceptualization of the research project, participant recruitment and diagnosis ascertainment of the validation cohort, protocol development, and manuscript preparation. NK contributed to design and conceptualization of the research project, analysis of all data including gene expression and protein measurements, paper writing, and manuscript submission.

Abbreviations: BAL, bronchoalveolar lavage; CART, classification and regression tree; CL, confidence interval; COPD, chronic obstructive pulmonary disease; DLCO%, percent predicted carbon monoxide diffusion capacity; FVC%, percent predicted forced vital capacity; HP, hypersensitivity pneumonitis; HRCT, high-resolution computed tomography; IPF, idiopathic pulmonary fibrosis; MMP, matrix metalloproteinase; NSIP, nonspecific interstitial pneumonia; ROC, receiver operating characteristic curve; SAM, significance analysis of microarrays.

References

Peripheral Blood Proteins in IPF


Editors’ Summary

Background. Idiopathic pulmonary fibrosis (IPF) is a serious disease in which the lungs become progressively scarred or thickened for unknown reasons. In healthy people, air is taken in through the mouth or nose and travels down the windpipe into tubes in the lungs called the airways. Each airway has many small branches that end in alveoli, tiny air sacs with thin walls that are surrounded by small blood vessels called capillaries. When air reaches the alveoli, the oxygen in it passes into the bloodstream and is taken to the organs of the body to keep them working. In IPF, the alveoli and the space around them (the “interstitial” area) gradually become scarred and thickened, which stops oxygen’s movement into the bloodstream. When only small areas of the lung are scarred, IPF may cause no symptoms. But, as more of the lung becomes damaged, IPF eventually causes breathlessness, even when resting. There is no effective treatment for IPF, although steroids and drugs that suppress the body’s immune system are often tried in an attempt to slow its progression. On average, half of the people with IPF die within three years of diagnosis, often from respiratory or heart failure.

Why Was This Study Done? It can be difficult to diagnose IPF—there are many lung diseases with similar symptoms, including numerous other interstitial lung diseases—and currently, physicians can only follow the progression of IPF by repeatedly testing their patients’ lung function or by doing multiple chest X-rays. If proteins could be identified whose level in blood indicated disease activity (so-called “peripheral blood biomarkers”), it would be easier to diagnose and monitor patients. In addition, the identification of such biomarkers might suggest new drug targets for the treatment of IPF. In this study, the researchers look for peripheral blood biomarkers in IPF by using a “multiplex analysis” system to measure the level of several proteins in patient blood samples simultaneously.

What Did the Researchers Do and Find? The researchers measured the levels of 49 plasma proteins (plasma is the fluid part of blood) in 74 patients with IPF and 53 healthy people (controls) and used a technique called “recursive partitioning” to define a five-protein signature that distinguished patients from unaffected study participants (controls). Matrix metalloproteinase 7 (MMP7) and MMP1—the two plasma proteins whose levels were most increased in patients with IPF compared to controls—were key components of this signature. Concentrations of MMP7 and MMP1 were higher in bronchoalveolar lavage samples (fluid obtained by washing out the lungs with saline) and in lung tissue samples from patients with IPF than in similar samples taken from healthy individuals. Plasma concentrations of MMP7 and MMP1 were significantly higher in patients with IPF than in patients with hypersensitivity pneumonitis, an interstitial lung disease that mimics IPF, but not increased in patients with chronic obstructive pulmonary disease or sarcoidosis, two other lung diseases. In an independent validation group, patients with IPF and familial pulmonary fibrosis had increased plasma concentrations of MMP7 and MMP1 that correlated with the severity of their disease. In addition, MMP7 concentrations were raised in close relatives of people with familial pulmonary fibrosis who had normal lung function tests but some lung scarring.

What Do These Findings Mean? These findings provide evidence for a protein signature in the blood for IPF and suggest MMP1 and MMP7 may be useful as biomarkers for IPF. These two matrix metalloproteinases have previously been suggested to be involved in the development of IPF. However, additional work is probably needed to confirm that increased plasma concentrations MMP7 and MMP1 are specific for IPF, since it may be that these markers will not distinguish IPF from other interstitial lung diseases.

Additional Information. Please access these Web sites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.0050093.

- Read a related PLoS Medicine Perspective article
- The MedlinePlus Encyclopedia has a page on idiopathic pulmonary fibrosis (in English and Spanish) and on pulmonary fibrosis
- The US National Heart Lung and Blood Institute and the British Lung Foundation also provide information on IPF for patients and relatives
- Some of the researchers involved in this study provide more details about what might go wrong in IPF in a recent PLoS Medicine article